Changes in Beneficial Ownership · 4
Evommune, Inc.
EVMNNYSEEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
primarydocument.xml
Filing details
- Report period
- 2026-11-13
- Issuer
- Evommune, Inc.
- Issuer CIK
- 0002044725
- Trading symbol
- EVMN
Reporting owner 1
- Name
- Bauer Eugene
- Reporting owner CIK
- 0001678620
- Relationship
- Director · Officer
- Officer title
- Chief Medical Officer
- Address
- C/O EVOMMUNE, INC., 1891 PAGE MILL ROAD, PALO ALTO, CA, 94304
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to buy) | 18.44 | 2026-11-13 | D · Form 4[F1] | 100,000.00 | D | [F2] | [F3] | 2035-12-07 | Common Stock | 100,000.00 | 0.00 | D |
| Stock Option (Right to buy) | 7.63 | 2026-11-13 | A · Form 4[F1] | 100,000.00 | A | [F2] | [F3] | 2035-12-07 | Common Stock | 100,000.00 | 100,000.00 | D |
| Stock Option (Right to buy) | 26.77 | 2026-11-13 | D · Form 4[F4] | 51,117.00 | D | [F2] | [F5] | 2036-04-15 | Common Stock | 51,117.00 | 0.00 | D |
| Stock Option (Right to buy) | 7.63 | 2026-11-13 | A · Form 4[F4] | 51,117.00 | A | [F2] | [F5] | 2036-04-15 | Common Stock | 51,117.00 | 51,117.00 | D |
Table key
- D · Form 4
- Disposition to the issuer under Rule 16b-3(e)
- D
- Direct
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
Footnotes
- F1
- The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on December 8, 2025.↩ 1↩ 2
- F2
- The transaction reported herein reflects a one-time stock option repricing (the "Option Repricing") pursuant to which the exercise price of the reported option has been amended to reduce the exercise price to $7.63 per share. If the Reporting Person exercises this option prior to the earliest of: (i) November 13, 2027; (ii) a Change in Control, as defined in the Issuer's 2025 Equity Incentive Plan (the "2025 Plan"); and (iii) the Reporting Person's death or Disability or termination of employment by the Issuer without Cause (each as defined in the 2025 Plan) or resignation following a Change in Control for Good Reason (as defined in the Reporting Person's employment agreement, if applicable), then the Reporting Person will be required to pay a premium exercise price equal to the original exercise price per share of such option.↩ 1↩ 2↩ 3↩ 4
- F3
- One fourth (1/4) of the shares subject to the option award shall vest on December 8, 2026 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.↩ 1↩ 2
Signature 1
- Signed
- /s/ Gregory S. Moss, Attorney-in-Fact
- Date
- 2026-11-17
Company context
Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.